-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On the 8th, Huadong Medicine announced that its wholly-owned subsidiary, Zhongmei Huadong, received the approval of the State Food and Drug Administration for the issuance of the "Drug Registration Certificate" for metformin and enpagliflozin tablets (I)
.
Metformin is a biguanide oral hypoglycemic drug
.
Metformin Enpagliflozin Tablets is a compound of two hypoglycemic drugs with complementary mechanisms of action.
Up to now, in addition to the original research company, only one company in East China, China and the United States has obtained the registration certificate for metformin and enpagliflozin tablets
.
According to the query of the IQVIA database, the global sales of this product in 2020 will be 505 million U.
As of the date of this announcement, the company's accumulated direct R&D investment for metformin and enpagliflozin tablets was approximately RMB 18.